In the Quest for New Horizons: Evaluating Novel Therapeutic Approaches for Tuberculosis Treatment

Tuberculosis (TB) in humans, caused by Mycobacterium tuberculosis, is a significant global health concern, resulting in high disease burden and mortality each year which together make it the world’s topmost infectious killer. The emergence of multidrug-resistant tuberculosis (MDR-TB) in recent decades has further exacerbated the present situation and warrants an urgent need to develop and investigate innovative treatment regimes. This study aims to assess the therapeutic potential of newly identified drug candidates, namely Bedaquiline, Delamanid, and Linezolid, in treating MDR-TB. We adopted a consolidated and integrated approach encompassing a thorough literature review, empirical experimental studies, multiple sequence alignments, and computational analyses, towards an in-depth analysis of the gene targets of these drugs and their efficacy in M. tuberculosis. Our findings indicate the significant potential of these drugs for tackling and treating drug-resistant TB, especially when synergized with prevailing first-line and second-line drugs. Notably, our results show a stark difference in the proteins and enzymes targeted by these drugs in mycobacteria versus those of the representative gut bacteria, providing a rationale for the minimal or mild side effects while administering these drugs in TB patients. Despite current infectious disease crises, including the COVID-19 disease, developing novel antibiotic treatments remains paramount against several serious bacterial pathogens. Our research offers a renewed perspective on enhancing therapeutic interventions by delving into drug combinatorial therapy against deadly infections, akin to those employed against drug-resistant tuberculosis. This research was supported by CUNY Research Foundation, NIH Bridges grant 5T34GM137858-04 (NIH NIGMS), and CUNY Research Scholars Program (CRSP). Dr. Richa Gupta served as the Principal Investigator and Research Mentor, and is the recipient of the Cycle 48 PSC-CUNY research award and Community College Research Grant (CCRG); Selassie Mawuko, Aminata Traore, and Bibi-Sakeena Khemraj were supported by the NIH Bridges Undergraduate Research Scholarship; and Anna Steto was supported by the CRSP Undergraduate Research Scholarship. This research was supported by CUNY Research Foundation, NIH Bridges grant 5T34GM137858-04 (NIH NIGMS), and CUNY Research Scholars Program (CRSP). This abstract was presented at the American Physiology Summit 2025 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.

Authors

Institutions

Publication Details

Journal
Physiology
Published
2025-05-01
DOI
https://doi.org/10.1152/physiol.2025.40.s1.1987
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In the Quest for New Horizons: Evaluating Novel Therapeutic Approaches for Tuberculosis Treatment

Richa Gupta, A. Traoré, Selassie Mawuko, Bibi-Sakeena Khemraj et al.
Physiology
Tuberculosis Research and Epidemiology
article

In the Quest for New Horizons: Evaluating Novel Therapeutic Approaches for Tuberculosis Treatment

Richa Gupta, A. Traoré, Selassie Mawuko, Bibi-Sakeena Khemraj, Anna Steto
article en

Abstract

Tuberculosis (TB) in humans, caused by Mycobacterium tuberculosis, is a significant global health concern, resulting in high disease burden and mortality each year which together make it the world’s topmost infectious killer. The emergence of multidrug-resistant tuberculosis (MDR-TB) in recent decades has further exacerbated the present situation and warrants an urgent need to develop and investigate innovative treatment regimes. This study aims to assess the therapeutic potential of newly identified drug candidates, namely Bedaquiline, Delamanid, and Linezolid, in treating MDR-TB. We adopted a consolidated and integrated approach encompassing a thorough literature review, empirical experimental studies, multiple sequence alignments, and computational analyses, towards an in-depth analysis of the gene targets of these drugs and their efficacy in M. tuberculosis. Our findings indicate the significant potential of these drugs for tackling and treating drug-resistant TB, especially when synergized with prevailing first-line and second-line drugs. Notably, our results show a stark difference in the proteins and enzymes targeted by these drugs in mycobacteria versus those of the representative gut bacteria, providing a rationale for the minimal or mild side effects while administering these drugs in TB patients. Despite current infectious disease crises, including the COVID-19 disease, developing novel antibiotic treatments remains paramount against several serious bacterial pathogens. Our research offers a renewed perspective on enhancing therapeutic interventions by delving into drug combinatorial therapy against deadly infections, akin to those employed against drug-resistant tuberculosis. This research was supported by CUNY Research Foundation, NIH Bridges grant 5T34GM137858-04 (NIH NIGMS), and CUNY Research Scholars Program (CRSP). Dr. Richa Gupta served as the Principal Investigator and Research Mentor, and is the recipient of the Cycle 48 PSC-CUNY research award and Community College Research Grant (CCRG); Selassie Mawuko, Aminata Traore, and Bibi-Sakeena Khemraj were supported by the NIH Bridges Undergraduate Research Scholarship; and Anna Steto was supported by the CRSP Undergraduate Research Scholarship. This research was supported by CUNY Research Foundation, NIH Bridges grant 5T34GM137858-04 (NIH NIGMS), and CUNY Research Scholars Program (CRSP). This abstract was presented at the American Physiology Summit 2025 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.

PhysiologyVol. 40(S1)
LaGuardia Community College (US)
Openalex Percentile: Top 82%
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.